# Treatment of benign biliary strictures with expandable biodegradable stents: Safety and efficacy in a single center

## TL;DR

This study explores the use of biodegradable stents for treating benign biliary strictures, showing promising safety and effectiveness in a small patient group.

## Contribution

The study introduces the use of expandable bioresorbable stents for selected benign biliary strictures, including intrahepatic locations.

## Key findings

- Technical success was achieved in all five procedures with no adverse events.
- Clinical success was observed in 80% of patients after stent implantation.
- Bioresorbable stents were used in uncommon stricture scenarios not well suited for traditional stents.

## Abstract

Benign biliary strictures (BBS) are commonly managed by progressive calibration using plastic or metallic stents. Although fully-covered metallic stents (FC-SEMS) enable immediate calibration to a larger diameter compared with plastic stents, they remain prone to migration and use is limited in intrahepatic and peri-hilar strictures. We report on using uncovered expandable bioresorbable stents (BRES) in a series of selected BBS patients.

This retrospective monocentric case series included all consecutive patients treated between 2023 and 2024. Patients were highly selected for uncommon situations for which usual stents were not well suited and followed for at least 12 months after the procedure. Technical success, clinical success, and adverse events (AEs) were systematically recorded.

Five procedures were performed in five patients with implantation of a total of eight UNITY-B stents. Three patients underwent internalization of an internal-external drainage across a bilio-digestive anastomotic stricture. One patient was treated with retrograde extra-anatomical endoscopic drainage for an anastomotic stricture. One patient underwent calibration of an intrahepatic stricture following radiofrequency of an IPMN-B. Technical success was achieved in all cases (100%), with clinical success observed in 80% of patients. No AEs were observed.

Use of bioresorbable UNITY-B stents appears feasible and safe for selected benign biliary strictures, including in intrahepatic locations. Further studies are needed to confirm these preliminary findings.